Issue 46 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

9

No.

46

December 02, 1983Dec 02, 1983

Free

DOWNLOAD THE PDF

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

Workshop Calls For Improved Surgical Oncology Training Programs

Recent Issues

Volume 52 | Issue 03 - January 23, 2026

Volume 52 | Issue 02 - January 16, 2026

Volume 52 | Issue 1 - January 09, 2026

Volume 51 | Issue 46 - December 19, 2025

Volume 51 | Issue 45 - December 12, 2025

Volume 51 | Issue 44 - December 05, 2025